Topical ocular delivery of nanoparticles with epoetin beta in Wistar Hannover rats

• Published in: Scientific reports Vol. 13; no. 1; p. 1559
• Main Authors: Silva, Beatriz, Gonçalves, Lídia M., São Braz, Berta, Delgado, Esmeralda
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.01.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154; 692/308; Administration, Topical; Animals; Chitosan; Chitosan - pharmacology; Cornea; Drug delivery; Erythropoietin; Erythropoietin - administration & dosage; Erythropoietin - analysis; Eye; Humanities and Social Sciences; Hyaluronic acid; Hyaluronic Acid - pharmacology; Immunofluorescence; multidisciplinary; Nanoparticles; Neuroprotection; Posterior Eye Segment - chemistry; Rats; Rats, Wistar; Retention time; Retina; Risk reduction; Science; Science (multidisciplinary); Topical medication
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-28845-0

Topical instillation of drugs targeting the posterior ocular segment is an expanding area of research. Chitosan and hyaluronic acid have remarkable mucoadhesive properties and potentially enhance pre-corneal retention time after topical instillation. Bearing this in mind, we explored the possibility of delivering epoetin beta (EPOβ) to the posterior segment of the eye in a chitosan-hyaluronic acid (CS/HA-EPOβ) nanoparticulate system using the topical route of administration. Complete ophthalmological examinations, electroretinography and microhematocrit evaluations were performed in Wistar Hannover (WH) rats, before and after topical administration of nanoparticles. The right eye received CS/HA-EPOβ and the left eye received only empty nanocarriers (control). Animals were split into 6 groups and at designated timepoints, all animals from each group (n = 3) were euthanized and both eyes enucleated. Retinal morphology and EPOβ ocular distribution were assessed, respectively, through hematoxylin and eosin (HE) and immunofluorescence staining. After topical administration, no adverse ocular signs were noted and no significant changes either in microhematocrits nor in electroretinographies were detected. During the study, intraocular pressure (IOP) was always kept within physiological range bilaterally. No histological changes were detected in any of the ocular globes. Immunofluorescence enabled the identification of EPOβ in the retina 12 h after the administration, its presence still being detectable at day 21. In conclusion, CS/HA nanoparticles could efficiently deliver EPOβ to the retina of WH rats after topical instillation, being considered biologically safe. Topical administration of this nanoformulation could be a valuable tool for retinal neuroprotection, decreasing risks associated with more invasive routes of administration, being cost effective and also increasing long-term patients’ compliance.